| A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury (NCT07347938) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2026-01-14 |
| A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury (NCT07107932) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2025-07-31 |
| A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants (NCT06710925) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2024-11-28 |
| A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy (NCT06068608) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2023-09-12 |
| A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants (NCT06083623) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2023-09-11 |
| Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (NCT05664750) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2022-12-22 |
| A Study of TNM001 in Chinese Healthy Preterm and Term Infants (NCT05630573) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2022-10-25 |
| A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine (NCT06607380) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2022-08-13 |
| Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers (NCT05625477) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2022-04-18 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults (NCT05842798) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2021-10-15 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults (NCT04629131) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2020-11-25 |